Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome

Bibliography

• Allen RP, Walters AS, Montplaisir J, Restless legs syndrome prevalence and impact: REST general population study. Arch Internal Med 2005;165:286-1292
   Google Scholar
• International Classification of Sleep Disorders: Diagnositic and Coding Manual 2005. 2nd edition. American Academy of Sleep Medicine, Westchester, IL; 2005
   Google Scholar
• Moyer DE, Zayas-Bazan J, Reese G. Restless legs syndrome: diagnostic time savers, treatment tips. J Fam Pract 2009;58:415-23
   PubMedGoogle Scholar
• Ohayon MM, Roth T. Prevalence of restless legs syndrome and periodic limb movements in the general population. J Psychosom Res 2002;53:547-54
   PubMed Web of Science ®Google Scholar
• Hening W, Walters AS, Allen RP, Impact, diagnosis, and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS Epidemology, Symptoms and Treatment) primary care study. Sleep Med 2004;5:237-46
   PubMed Web of Science ®Google Scholar
• Kageyama T, Kabuto M, Nitta M, Prevalences of periodic limb movement-like and restless legs-like symptoms among Japanese adults. Psychiatry Clin Neurosci 2000;54:296-8
   PubMed Web of Science ®Google Scholar
• Tan EK, Seah A, See SJ, Restless legs syndrome in an Asian population: a study in Singapore. Mov Disord 2001;16:577-9
   PubMed Web of Science ®Google Scholar
• Merlino G, Valente M, Serafini A, Gigli GL. Restless legs syndrome: diagnosis, epidemology, classification and consequences. Neurol Sci 2007;28(Suppl 1):S37-46
   Google Scholar
• Bassetti CL, Mauerhofer D, Gugger M, Restless legs syndrome: a clinical study of 55 patients. Eur Neurol 2001;45:67-74
   PubMed Web of Science ®Google Scholar
• Desautels A, Turecki G, Montplaisir G, Identification of a major suspectibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 2001;69:1266-70
   PubMed Web of Science ®Google Scholar
• Bonati MT, Ferini-Strambi L, Aridon P, Autosominal dominant restless legs syndrome maps on chromosome 14q. Brain 2003;126:1485-92
   PubMed Web of Science ®Google Scholar
• Chen S, Ondo WG, Rao S, Genomewide linkage scan identifies a novel suspectibility locus for Restless Legs Syndrome on chromosome 9p. Am J Hum Genet 2006;79:716-23
   PubMedGoogle Scholar
• Pichler I, Marroni F, Volpato CB, Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate. Am J Hum Genet 2006;79:716-23
   PubMed Web of Science ®Google Scholar
• Levchenko A, Provost S, Montplaisir JY, A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13. Neurology 2006;67:900-1
   PubMed Web of Science ®Google Scholar
• Stefansson H, Rye DB, Hicks A, A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007;357:639-47
   PubMed Web of Science ®Google Scholar
• Winkelman J, Schormair B, Lichtner P, Genome-wide association study of restless legs syndrome identifies common variantss in three genomic regions. Nat Genet 2007;39:1000-6
   PubMedGoogle Scholar
• Kushida CA. Pramipexole for the treatment of restless legs syndrome. Expert Opin Pharmacother 2006;7:441-51
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Sethi K, Kushida C, Pramipexole is efficacious and safe in treating RLS patients: results of a 12 weeks placebo-controlled, fixed dose study. Sleep Med 2005;6(Suppl 2):S74
   Google Scholar
• Hansen RA, Song L, Moore CG, Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. Pharmacotherapy 2009;29:255-62
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5:9-14
   PubMed Web of Science ®Google Scholar
• Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless leg syndrome with dopamine agonists. Arch Neurol 2004;61:1393-7
   PubMed Web of Science ®Google Scholar
• Dodd ML, Klos KJ, Bower JH, Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-81
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Benes H, Grote L, ; CALDIR Study Group. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 2007;22:696-703
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Sethi KD, Kushida CA, Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;7:407-17
   Google Scholar
• Trenkwalder C, Hening WA, Montagna P, Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008;23:2267-302
   PubMed Web of Science ®Google Scholar
• Walters AS, Wagner ML, Hening WA, Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993;16:327-32
   PubMed Web of Science ®Google Scholar
• Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry 1999;60:241-4
   PubMed Web of Science ®Google Scholar
• Boghen D, Lamothe L, Elie RA, The treatment of restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci 1986;13:245-7
   PubMed Web of Science ®Google Scholar
• Montagna P, de Bianchi LS, Zucconi M, Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand 1984;69:428-30
   PubMed Web of Science ®Google Scholar
• Davis BJ, Rajput A, Rajput ML, A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000;43:70-5
   PubMed Web of Science ®Google Scholar
• Grote L, Leissner L, Hedner J, A randomized, double-blind placebo controlled, multicenter study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 2009;24:1445-52
   PubMed Web of Science ®Google Scholar
• Earley CJ, Horska A, Mohamed MA, A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 2009;10:206-11
   PubMed Web of Science ®Google Scholar
• Saletu M, Anderer P, Saletu-Zyhlarz GM, Comparative placebo-controlled polysomnographic and psychometric studies on the acute effects of gabapentin versus ropinirole in restless legs syndrome. J Neural Transm 2010;117:463-73
   PubMed Web of Science ®Google Scholar
• Cundy KC, Branch R, Chernov-Rogan T, XP13512 ((±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl]-aminomethyl)-1-cyclohexane acetic acid), a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004;311:315-23
   PubMed Web of Science ®Google Scholar
• Cundy KC, Thamil A, Lin B, XP13512 ((±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl]-aminomethyl)-1-cyclohexane acetic acid), a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004;311:324-33
   PubMed Web of Science ®Google Scholar
• Cundy KC, Sastry S, Luo W, Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008;48:1378-88
   PubMed Web of Science ®Google Scholar
• Lal R, Sukbuntherng J, Luo W, The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin enacarbil. Int J Clin Pharmacol Ther 2010;48:120-8
   PubMed Web of Science ®Google Scholar
• Kushida CA, Walters AS, Becker P, A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009;32:159-68
   PubMed Web of Science ®Google Scholar
• Kushida CA, Becker P, Perkins T, XP13512 improves symptoms and sleep disturbance in RLS patients: results of a 2-week, randomized, double-blind, placebo-controlled cross-over polysomnography trial. Sleep 2006;29(Suppl S):A278
   Google Scholar
• Walters AS, Kushida CA, Becker PM, XP13512 improves restless legs syndrome (RLS) patient sleep and symptoms in two double-blind, randomized, placebo-controlled studies. Ann Neurol 2008;60(Suppl):S83
   Google Scholar
• Walters AS, Ondo WG, Kushida CA, Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2009;32:311-20
   PubMed Web of Science ®Google Scholar
• Kushida CA, Becker PM, Ellenbogen AL, Randomized, double-blind placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009;72:439-46
   PubMed Web of Science ®Google Scholar
• Lee D, Ziman R, Perkins A, Efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome: a randomized, double-blind, placebo-controlled study. Sleep 2009;32(Suppl):A300
   Google Scholar
• Cramer Bornemann MA, Bogan RK, Kushida CA, A maintainance efficacy study of gabapentin enacarbil versus placebo in subjects with restless legs syndrome. Sleep 2009;32(Suppl):A304
   Google Scholar
• Garcia-Borreguero D, Larrosa O, de la Llave Y, Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002;59:1573-9
   PubMed Web of Science ®Google Scholar